cyrilzakka/clinical-trials huggingface dataset:
Hip Related Functional Limitations in Individuals With Idiopathic Scoliosis

The aim of this study is to examine the functional parameters of hip and jaw in terms of scoliosis degree and scoliosis pattern in individuals with idiopathic scoliosis.

In this study investigators will examine the hip functional parameters and jaw functional parameters separately.

In hip study hip functional parameters will be evaluated for determining the correlation between scoliosis degree/pattern and hip functions.

In jaw study jaw functional parameters will be evaluated for determining the correlation between scoliosis degree/pattern and hip functions.

Eligibility Criteria:
Inclusion Criteria: (for all hip and jaw evaluation)

* Having been diagnosed with adolescent idiopathic scoliosis by a specialist physician with existing anterior-posterior and lateral lateral radiographs,
* Primary curvature over 10 degrees in the coronal plane according to the Cobb method,
* Being literate,
* To cooperate in answering and implementing evaluation scales,
* Children with written consent from their parents and themselves will be included.

Exclusion Criteria: (for hip evaluation)

* Having any systemic illness,
* Spinal surgery history,
* Presence of any acute or chronic disease other than scoliosis,
* Inadequate quality to examine the measurement parameters of the current vertebral radiography,
* Use of musical instruments,
* Long-term and professional sports.

Exclusion Criteria: (for jaw evaluation)

* Having any systemic illness,
* Spinal surgery history,
* Presence of any acute or chronic disease other than scoliosis,
* Aesthetics or any injection intervention in the face and neck area,
* Spinal surgery history,
* Orthodontic treatment,
* Use of musical instruments,
* Long-term and professional sports.
HPV as a Possible Cause of Azoospermia

Azoospermia is found in 5-20% of all men suffering from infertility, and in more than 20% azoospermia remains unexplained. The investigators suggest, that HPV may be an etiological factor in azoospermia and reduced sperm production.

The investigators plan to examine the occurrence of HPV in testicular tissue from 100 azoospermic men and to compare with the HPV occurrence in testicular tissue from a control group of 40 normal, healthy men undergoing vasectomy. Since HPV, in a recent Danish study, was detected on sperm in 16% of 188 randomly selected semen donors, the investigators also plan to examine the occurrence of HPV on sperm ejaculated during the last week before vasectomy. If HPV should be found in testicular tissue from men belonging to the control group, it will be highly relevant to compare with the HPV occurrence on sperm ejaculated from the men in concern.

A Linear Array HPV Genotyping Kit from Roche will be used for detection of HPV in testicular tissue and ejaculates. In total, with this test kit 37 HPV genotypes are examined for, including 13 high risk types.


Eligibility Criteria:
Inclusion Criteria:

* Men with azoospermia (Group 1) and proven fertile men undergoing vasectomy (Group 2)

Exclusion Criteria:

* Men with testicular abnormalities (Group 2)
* Men who do not understand the purpose and possible consequences of the study (both groups)
Identification of New Serum Markers for Detection of Abuse With Erythropoietin

Epo increases red blood cell production and hence the amount of oxygen that can be transported around the body. It is shown that prolonged use of synthetic Epo (rHuEpo) leads to an increase in the period of time a given physical work can be performed, therefore it will continue to be abused by athletes, especially in endurance sports.

The existing method for measuring the abuse of rHuEpo approved by the World Anti-Doping Agency (WADA) is based on differences in the sugar groups bound to rHuEpo and Epo produced in the body, respectively.

Proteomics is a method by which one can look at all the proteins in blood at the same time. Even proteins that have changed very little can be distinguished. The main objective of this project is to investigate the effect of prolonged treatment with rHuEpo on changes in blood proteins in healthy young men.


Eligibility Criteria:
Inclusion Criteria:

* healthy men
* age 18-35
* untrained
* BMI: 20-25

Exclusion Criteria:

* smokers
* chronic diseases
* malignancy (former or present)
* alcohol, drug or EPO abuse
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC

The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC) with progression of disease during or after at least 1 systemic therapy.


Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* ECOG Status: PS 0-1 \& PS 2
* Subjects with histologically or cytologically-documented SqNSCLC
* Subjects must have experienced disease progression or recurrence during or after one prior platinum doublet-based chemotherapy regimen
* Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria
* Subjects with treated or asymptomatic CNS metastases
* Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
* Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy, immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or standard or investigational agents for treatment of NSCLC, must be completed 28 days prior to the first dose of nivolumab
* Males and Females, ages 18 or older

Exclusion Criteria:

* Subjects with untreated, symptomatic CNS metastases
* Subjects with carcinomatous meningitis
* Subjects with active, known or suspected autoimmune disease.
* Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.
Patient Outcomes from Second Film-readers and Test Threshold Relaxation in Breast Screening

Analysis of women's medical records to understand the impact of previous changes to breast cancer screening (increase from one to two clinicians examining each woman's mammograms, and what proportion of women they recall for further tests)

Retrospective observational study examining the records and outcomes of women who attended breast cancer screening between 1988 and 2016. Linkage of records from the breast screening service, the cancer registry, and mortality. Analysis of whether changing the threshold for whether to recall women for further tests or the number of clinicians examining the mammograms for signs of cancer affects outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Women who attended the English National Health Service (NHS) breast cancer screening service at least once between 1988 and 2016, aged between 47 and 73
* All eligible episodes of screening for each woman (we expect women to be screened around 7 times each)

Exclusion Criteria:

* Women who did not attend routine English NHS Breast screening service within the specified date and age range, even if they attended symptomatic breast cancer services, high risk (family history) breast screening services, or if they were referred for mammograms by their general practitioner
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There is only one currently FDA-approved treatment, adalimumab, but only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.


Eligibility Criteria:
Inclusion Criteria:

* Able and willing to provide informed consent
* English speaking
* Age \>= 18years of age
* Diagnosis of hidradenitis suppurativa by a dermatologist
* Women who are not post-menopausal (at least 12 months of non-therapy induced amenorrhea) or surgically sterile (e.g. absence of ovaries and/or uterus) must remain abstinent or use a highly effective form of birth control (e.g. oral contraception, transdermal patch, barrier, intrauterine device). Periodic abstinence and early withdraw are not acceptable methods
* Able to comply to study measures in the opinion of the investigator.
* Stable doses of all medications for 30 days prior to baseline

Exclusion Criteria:

* Non-English speaking
* Refusal or inability to provide informed consent
* Planning on moving within 6 months from start of study
* Allergy to neomycin or vancomycin
* Anaphylactic food allergies
* Pregnancy, breastfeeding or planning pregnancy during study period (negative pregnancy test needed for persons of childbearing potential)
* Use of any topical or oral antibiotics within 30 days of randomization
* Use of any oral antibiotics within 90 days of randomization
* History of inflammatory bowel disease
* Extensive bowel resection (e.g., subtotal colectomy, substantial removal of small bowel)
* No major bowel surgery within 4 weeks prior to baseline or planned major surgery during the study period
* No active skin disease other than HS that could interfere with assessments
Efficacy Study of the Music Glove Patients With Spinal Cord Injuries

Investigators are trying to determine the therapeutic effect of the music glove and conventional hand exercise program to patients with spinal cord injuries. All participants will be randomized into two groups: AB and BA. They will all exercise at least 3 times a week for 3 weeks with minimum of 3 hours of exercise time per week. Participants will receive the other intervention at their 3 week post-therapy follow-up visits. Clinical evaluations will be performed at baseline 1 and 2 (3 to 10 days apart), post-therapy after the first intervention, 3-week post-therapy follow up, post-therapy after the second intervention, and 3-week post-second intervention follow up visits.


Eligibility Criteria:
Inclusion Criteria:

* History of spinal cord injury affecting the arm and hand functions, at least 6 months prior to enrollment
* Upper extremity weakness as measured on a standard clinical scale
* No active major psychiatric problems, or neurological/orthopedic problems affecting the training upper extremity
* No active major neurological disease other than the spinal cord injury
* Absence of pain in the affected upper extremity

Exclusion Criteria:

* Severe tone at the affected upper extremity as measured on a standard clinical scale
* Severe sensory/proprioception deficit at the affected upper extremity as measured on a standard clinical scale
* Difficulty in understanding or complying with instructions given by the experimenter
* Inability to perform the experimental task that will be studied
* Increased pain with movement of the training upper extremity
EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )

Prehospital providers encounter patients with suspected stroke frequently. Stroke and COVID-19 are related potentially putting these healthcare workers at risk of COVID-19 infection. In addition, prehospital providers need tools to help triage large vessel stroke patients to comprehensive stroke centers.

This observational prospective study will document COVID-19 status on patients seen in the prehospital environment for suspected stroke. This will provide an estimate of how frequently stroke occurs in stroke and also the exposure risk to providers in this setting.

Additionally, patients will have a headset placed to record their headpulse during the encounter. These measurements will be used to further develop an analytic model used to predict the presence of large vessel occlusion (LVO) stroke. This may help create a device that can be used in the prehospital environment to aid in the trade decision of destination hospital.

Eligibility Criteria:
Inclusion Criteria:

* suspected stroke in the prehospital setting
* patient at risk for COVID-19

Exclusion Criteria:

* scalp laceration
* Patient refusal
* Prisoner, other vulnerable population
* Prehospital provider feels that the recording may interfere with care
A Review of Precice Intramedullary Limb Lengthening (IMLL) System for Limb Lengthening Procedures in Children.

This study will look at how safe and effective limb lengthening surgeries are for the femur and tibia in children 12 years old and younger. We will examine any complications from the surgery, the results of X-rays, and feedback from patients. The study will involve the Precice Intramedullary Limb Lengthening (IMLL) System and external fixator devices for limb lengthening.

As a retrospective chart review, all patients involved in this study will have undergone surgery for their limb length discrepancy according to the standard of care of the practitioner using either the Precice IMLL or an external fixator. Under this protocol, available patient outcomes, plain radiographs, and complications will be obtained from the existing medical records of all eligible index surgeries. An index surgery is defined as the first limb lengthening surgery performed by a study investigator on the index bone with either the Precice IMLL or an external fixator. Each patient may have up to 4 eligible index surgeries (right and left femur, right and left tibia) and be included in both the Precice IMLL and external fixator groups.

Eligibility Criteria:
Inclusion Criteria:

* All potential index surgeries must meet the inclusion criteria below in order to be considered for enrollment:

  1. Patient was 12 years of age or younger at the time of the index surgery.
  2. Diagnosis of femoral or tibial limb length discrepancy greater than or equal to 2.0 cm.
  3. Limb length discrepancy secondary to congenital or acquired etiologies.
  4. Patients received limb lengthening treatment of the femur or tibia with the Precice IMLL System or an external fixator limb lengthening device.
  5. Minimum medullary canal diameter ≥6 mm in the treated bone - Precice IMLL System treatment group only.
  6. Closed or nonfunctioning physeal growth plates in the treated bone - Precice IMLL System treatment group only.
  7. Minimum of 12 months of follow-up.
  8. Available medical and radiographic records preoperatively through consolidation.

Exclusion Criteria:

* Index surgeries will be excluded from consideration for the study if they meet any of the following criteria:

  1. Patients with unresolved limb lengthening-related adjacent joint contractures (loss of range of motion), subluxation, or dislocation prior to the index surgical procedure.
  2. Patients with uncorrected coronal or sagittal plane angular malalignment following the index surgical procedure.
  3. Patients with unresolved complications related to previous limb lengthening on the index or different limbs, including unhealed pin sites and/or residual bone infection (from external fixator devices) on the index limb.
  4. Patients with femoral head osteonecrosis from a previous implantation of a femoral nail prior to the index surgical procedure.
  5. Patients with a previous implantation of a femoral or tibial nail across an open physeal growth plate prior to the index surgical procedure.
2kcal Tube Feed Study

The primary aim of this study is to investigate the effects of a plant-based, high energy, high protein tube feed with and without inclusion of fibre on gastrointestinal tolerance in adult patients who require nutritional support via enteral tube feeding over a 28-day period, followed by a 12-month follow-up. Secondary aims are to determine the effects on compliance, acceptability, anthropometry, nutrient intake, and physical function. This is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period and a 1-year follow-up.


Eligibility Criteria:
Inclusion Criteria:

* Male or female
* ≥16 years of age
* Using or requiring an enteral tube feed in the community as part of nutritional management plan
* Expected to receive at least 1000kcal/day (one bottle) from one of the study products

Exclusion Criteria:

* Receiving parenteral nutrition
* Patients with major hepatic dysfunction (i.e., decompensated liver disease)
* Patients with major renal dysfunction (i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD))
* Patients receiving inpatient care
* Known pregnancy or lactation
* Participation in other clinical intervention studies within 1 month of this study
* Allergy to any study product ingredients
* Investigator concern regarding ability or willingness of patient to comply with the study requirements.
The Effect of Different Videolaryngoscopes on Intubation Success in Difficult Airway Patients

Mallampati score \> 3 generally indicate difficult airway and difficult intubation. Most anesthesiologist usually use this score system to predict difficult airway management. Different laryngoscopes may be useful in management of difficult airway. This study designed to compare different videolaryngoscopes in intubation success in patient of Mallampati score\>3.


Eligibility Criteria:
Inclusion Criteria:

* mallampati score \>3

Exclusion Criteria:

* patient refusal
Biomarkers of Food Intake Using a Cross-over Feeding Study

Assessment of dietary intake is key for understanding the links between diet and health. Here, researchers will study molecules in urine samples to give them an insight into what people have eaten. These new molecules are called dietary biomarkers. This study will help to identify new molecules that can act as biomarkers of commonly consumed foods. These can then be used in the assessment of diet, identification of diet-related diseases and used how to explain how a dietary intervention (programme) will work, thereby adding to scientific knowledge.

For biomarker discovery a cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption . Standard portions of the test food will be eaten on each occasion. Between the visits, participants will consume their habitual diet.

The samples will be analysed using the metabolomics platforms LC-MS and NMR spectroscopy. Both NMR and LC-MS data generated will undergo statistical analysis such as principal component analysis (PCA) and supervised analysis such as partial least squares-discriminant analysis (PLS-DA). Validation of such models will be performed using permutation testing.

Eligibility Criteria:
Inclusion Criteria:

1. Healthy adults aged 18-50 years old
2. BMI\<30.

Exclusion Criteria:

1. Smokers
2. Diagnosed health condition (chronic or infectious disease)
3. Taking medication (oral contraceptive pill is allowed)
4. Pregnant, lactating
5. Allergies/intolerances to any of specified test foods
Fish Oil Brain Delivery Study

Docosahexaenoic acid (DHA) is an essential omega-3 fish oil. DHA is critical to the structure and function of brain cells.

DHA fish oil has been shown to be beneficial in cognition in several animal studies; however, this effect in human studies is not clear. It is not known how much dietary fish oil can get into the human brain. Thus, exploring fish oil delivery in human brains is critical for designing appropriate interventions.

* The investigators goal is to study how different people deliver DHA to the brain.
* The study will only require two visits six months apart and involve taking DHA during these 6 months.
* Participants will receive DHA supplements for the study duration and a compensation for each study visit.
* Blood and cerebrospinal fluid levels of DHA will be measured before and after taking DHA.
* Brain imaging by MRI will be obtained at baseline and at conclusion of study
* This study will help us learn how much of the ingested DHA goes to the brain.

Eligibility Criteria:
Inclusion Criteria:

* ages 55 and above
* at risk of Alzheimer's disease such as family history of dementia
* women have to be postmenopausal

Exclusion Criteria:

1. Current smokers (or a recent history of smoking within less than 5 years),
2. Having a history of cardiovascular disease defined by a prior heart attack, coronary bypass or percutaneous luminal angioplasty, kidney failure or blindness.
3. a diagnosis of cancer in the past 6 months, uncontrolled hyper- or hypothyroidism
4. Taking anti-coagulants such as warfarin
5. Anyone consuming n-3 PUFA capsules for the last 3 months.
6. regular exercisers (\>5 X30min of aerobic exercise per week),
7. heavy drinkers (\>30 units of alcohol per week). One unit of alcohol is about equal to: half a pint of ordinary strength beer, lager or cider (3-4% alcohol by volume); or. a small pub measure (25 ml) of spirits (40% alcohol by volume); or. a standard pub measure (50 ml) of fortified wine such as sherry or port (20% alcohol by volume)
8. If participants have scores that lie 2 SD outside the means of the neuropsychiatry tests administered, they will have mild cognitive impairment. Participant's with mild cognitive impairment are excluded from this study.